Dolutegravir-induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication

Abstract

Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug-drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35-year-old male patient who was diagnosed with acquired sideroblastic anemia to Dolutegravir therapy.

Keywords: Dolutegravir; HIV; Naranjo scale; acquired sideroblastic anemia; adverse drug reaction.